The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Vasenina E.E.

Russian Medical Academy of Continuous Professional Education

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Contemporary approaches to clinical diagnosis and treatment of tau-protein accumulation related multisystem degenerations

Authors:

Vasenina E.E., Levin O.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10‑2): 22‑30

DOI: 10.17116/jnevro202012010222

Read: 5682 times

Download PDF (RU)
Contact the author
Table of contents

CONTEMPORARY APPROACHES TO CLINICAL DIAGNOSIS AND TREATMENT OF TAU-PROTEIN ACCUMULATION RELATED MULTISYSTEM DEGENERATIONS
CONTEMPORARY APPROACHES TO CLINICAL DIAGNOSIS AND TREATMENT OF TAU-PROTEIN ACCUMULATION RELATED MULTISYSTEM DEGENERATIONS

To cite this article:

Vasenina EE, Levin OS. Contemporary approaches to clinical diagnosis and treatment of tau-protein accumulation related multisystem degenerations. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10‑2):22‑30. (In Russ.)
https://doi.org/10.17116/jnevro202012010222

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):133-139
Abstract:

Tau-protein pathology is the basis of a great variety of neurodegenerative diseases. Misfolding tau-protein conformation structure is the key pathogenetic mechanism of development of such multisystem degenerations as progressive supranuclear palsy, corticobasal syndrome, and fronto-temporal degeneration, as well as relatively recently added primary age-associated tauopathies and others. This review presents current views on the pathogenesis of various forms of neurodegenerative pathology linked to tau-protein accumulation. Potential of clinical diagnosis and modern diagnostic criteria, as well as existing therapy approaches, are discussed.

Keywords:

tauopathy
progressive supranuclear palsy
corticobasal degeneration
diagnostic criteria
argyrophilic grain disease
tauopathy
progressive supranuclear palsy
corticobasal degeneration
diagnostic criteria
argyrophilic grain disease

Authors:

Vasenina E.E.

Russian Medical Academy of Continuous Professional Education

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Received:

06.07.2020

Accepted:

09.09.2020

Close metadata

References:

  1. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA. 1975;72(5):1858-1862. https://doi.org/10.1073/pnas.72.5.1858
  2. Kovacs GG. Tauopathies. Handb Clin Neurol. 2017;145:355-368.  https://doi.org/10.1016/B978-0-12-802395-2.00025-0
  3. Ling H. Untangling the tauopathies: Current concepts of tau pathology and neurodegeneration. Parkinsonism Relat Disord. 2018;46(suppl 1):34-38.  https://doi.org/10.1016/j.parkreldis.2017.07.031
  4. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5-21.  https://doi.org/10.1038/nrn.2015.1
  5. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA. 1988;85(11):4051-4055. https://doi.org/10.1073/pnas.85.11.4051
  6. Hagmann P, Cammoun L, Gigandet X, Gerhard S, Grant PE, Wedeen V, Meuli R, Thiran JP, Honey CJ, Sporns O. MR connectomics: Principles and challenges. Journal of Neuroscience Methods. 2010;194(1):34-45.  https://doi.org/10.1016/j.jneumeth.2010.01.014
  7. Vecchio F, Miraglia F, Maria Rossini P. Connectome: Graph theory application in functional brain network architecture. Clin Neurophysiol Pract. 2017;2:206-213. Published 2017 Oct 24.  https://doi.org/10.1016/j.cnp.2017.09.003
  8. Preti MG, Bolton TA, Van De Ville D. The dynamic functional connectome: State-of-the-art and perspectives. Neuroimage. 2017;160:41-54.  https://doi.org/10.1016/j.neuroimage.2016.12.061
  9. Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Molecular Psychiatry. 2019;24(8):1112-1134. https://doi.org/10.1038/s41380-018-0342-8
  10. Goedert M, Spillantini MG. Ordered Assembly of Tau Protein and Neurodegeneration. Adv Exp Med Biol. 2019;1184:3-21.  https://doi.org/10.1007/978-981-32-9358-8_1
  11. Kovacs GG. Astroglia and Tau: New Perspectives. Front Aging Neurosci. 2020;12:96. Published 2020 Apr 9.  https://doi.org/10.3389/fnagi.2020.00096
  12. Kim D, Kim HS, Choi SM, Kim BC, Lee MC, Lee KH, Lee JH. Primary Age-Related Tauopathy: An Elderly Brain Pathology Frequently Encountered during Autopsy. Journal of Pathology and Translational Medicine. 2019;53(3):159-163.  https://doi.org/10.4132/jptm.2019.03.14
  13. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, Nelson PT. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica. 2014;128(6):755-766.  https://doi.org/10.1007/s00401-014-1349-0
  14. Rösler TW, Tayaranian Marvian A, Brendel M, Nykänen NP, Höllerhage M, Schwarz SC, Hopfner F, Koeglsperger T, Respondek G, Schweyer K, Levin J, Villemagne VL, Barthel H, Sabri O, Müller U, Meissner WG, Kovacs GG, Höglinger GU. Four-repeat tauopathies. Progress in Neurobiology. 2019;180:101644. https://doi.org/10.1016/j.pneurobio.2019.101644
  15. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement disorders: official journal of the Movement Disorder Society. 2017;32(6):853-864.  https://doi.org/10.1002/mds.26987
  16. Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017;16(7):552-563.  https://doi.org/10.1016/S1474-4422(17)30157-6
  17. Lamb R, Rohrer JD, Lees AJ, Morris HR. Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. Curr Treat Options Neurol. 2016;18(9):42.  https://doi.org/10.1007/s11940-016-0422-5
  18. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Tröster AI, Vidailhet M, Weiner WJ. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503.  https://doi.org/10.1212/WNL.0b013e31827f0fd1
  19. Vasenina EE, Levin OS. Pervichnye progressiruiushchie afazii [Primary progressive aphasias]. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2014;114(6 Pt 2):3-12. (In Russ.).
  20. Van Mossevelde S, Engelborghs S, van der Zee J, Van Broeckhoven C. Genotype-phenotype links in frontotemporal lobar degeneration. Nat Rev Neurol. 2018;14(6):363-378.  https://doi.org/10.1038/s41582-018-0009-8
  21. Sivasathiaseelan H, Marshall CR, Agustus JL, Benhamou E, Bond RL, van Leeuwen J, Hardy C, Rohrer JD, Warren JD. Frontotemporal Dementia: A Clinical Review. Seminars in Neurology. 2019;39(2):251-263.  https://doi.org/10.1055/s-0039-1683379
  22. Van Mossevelde S, Engelborghs S, van der Zee J, Van Broeckhoven C. Genotype-phenotype links in frontotemporal lobar degeneration. Nat Rev Neurol. 2018;14(6):363-378.  https://doi.org/10.1038/s41582-018-0009-8
  23. Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci. 2011;45(3):384-389.  https://doi.org/10.1007/s12031-011-9589-0
  24. Baizabal-Carvallo JF, Jankovic J. Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol. 2016;12(3):175-185.  https://doi.org/10.1038/nrneurol.2016.14
  25. Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci. 2011;45(3):384-389.  https://doi.org/10.1007/s12031-011-9589-0
  26. Molina JA, Probst A, Villanueva C, Jiménez-Jiménez FJ, Madero S, Torres N, Bermejo F. Primary progressive aphasia with glial cytoplasmic inclusions. European Neurology. 1998;40(2):71-77.  https://doi.org/10.1159/000007961
  27. Bigio EH, Lipton AM, Yen SH, Hutton ML, Baker M, Nacharaju P, White CL, 3rd, Davies P, Lin W, Dickson DW. Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. Journal of Neuropathology and Experimental Neurology. 2001;60(4):328-341.  https://doi.org/10.1093/jnen/60.4.328
  28. Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR, Ghetti B. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci USA. 1997;94(8):4113-4118. https://doi.org/10.1073/pnas.94.8.4113
  29. Josephs KA, Katsuse O, Beccano-Kelly DA, Lin WL, Uitti RJ, Fujino Y, Boeve BF, Hutton ML, Baker MC, Dickson DW. Atypical progressive supranuclear palsy with corticospinal tract degeneration. Journal of Neuropathology and Experimental Neurology. 2006;65(4):396-405.  https://doi.org/10.1097/01.jnen.0000218446.38158.61
  30. Ahmed Z, Bigio EH, Budka H, Dickson DW, Ferrer I, Ghetti B, Giaccone G, Hatanpaa KJ, Holton JL, Josephs KA, Powers J, Spina S, Takahashi H, White CL, 3rd, Revesz T, Kovacs GG. Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathologica. 2013;126(4):537-544.  https://doi.org/10.1007/s00401-013-1171-0
  31. Das S, Ishaque A. Argyrophilic grain disease: a clinicopathological review of an overlooked tauopathy. Folia Neuropathol. 2018;56(4):277-283.  https://doi.org/10.5114/fn.2018.80859
  32. Rodriguez RD, Grinberg LT. Argyrophilic grain disease: An underestimated tauopathy. Dement Neuropsychol. 2015;9(1):2-8.  https://doi.org/10.1590/S1980-57642015DN91000002
  33. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC. Neuropathology of cognitively normal elderly. Journal of Neuropathology and Experimental Neurology. 2003;62(11):1087-1095. https://doi.org/10.1093/jnen/62.11.1087
  34. Asaoka T, Tsuchiya K, Fujishiro H, Arai T, Hasegawa M, Akiyama H, Iseki E, Oda T, Onaya M, Tominaga I. Argyrophilic grain disease with delusions and hallucinations: a pathological study. Psychogeriatrics: the official journal of the Japanese Psychogeriatric Society. 2010;10(2):69-76.  https://doi.org/10.1111/j.1479-8301.2010.00318.x
  35. Grau-Rivera O, Gelpi E, Rey MJ, Valldeoriola F, Tolosa E, Compta Y, Martí MJ. Prominent psychiatric symptoms in patients with Parkinson’s disease and concomitant argyrophilic grain disease. Journal of Neurology. 2013;260(12):3002-3009. https://doi.org/10.1007/s00415-013-7101-1
  36. Giagkou N, Stamelou M. Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism. CNS Drugs. 2018;32(9):827-837.  https://doi.org/10.1007/s40263-018-0551-3
  37. Jitsuki S, Takemoto K, Kawasaki T, Tada H, Takahashi A, Becamel C, Sano A, Yuzaki M, Zukin RS, Ziff EB, Kessels HW, Takahashi T. Serotonin mediates cross-modal reorganization of cortical circuits. Neuron. 2011;69(4):780-792.  https://doi.org/10.1016/j.neuron.2011.01.016
  38. Vasenina EE, Levin OS. Speech disorders and anxiety: interaction mechanisms and therapy potential. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2020;120(4):136-144.  https://doi.org/10.17116/jnevro2020120041136
  39. Herrmann N, Black SE, Chow T, Cappell J, Tang-Wai DF, Lanctôt KL. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2012;20(9):789-797.  https://doi.org/10.1097/JGP.0b013e31823033f3
  40. Alam S, Lingenfelter KS, Bender AM, Lindsley CW. Classics in Chemical Neuroscience: Memantine. ACS Chem Neurosci. 2017;8(9):1823-1829. https://doi.org/10.1021/acschemneuro.7b00270
  41. Dominguez E, Chin TY, Chen CP, Wu TY. Management of moderate to severe Alzheimer’s disease: focus on memantine. Taiwan J Obstet Gynecol. 2011;50(4):415-423.  https://doi.org/10.1016/j.tjog.2011.10.004
  42. Kishi T, Matsunaga S, Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat. 2015;11:2883-2885. Published 2015 Nov 12.  https://doi.org/10.2147/NDT.S94430
  43. Johnson NA, Rademaker A, Weintraub S, Gitelman D, Wienecke C, Mesulam M. Pilot trial of memantine in primary progressive aphasia. Alzheimer Dis Assoc Disord. 2010;24(3):308.  https://doi.org/10.1097/WAD.0b013e3181cf468d
  44. Boxer AL, Lipton AM, Womack K, Merrilees J, Neuhaus J, Pavlic D, Gandhi A, Red D, Martin-Cook K, Svetlik D, Miller BL. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Disease and Associated Disorders. 2009;23(3):211-217.  https://doi.org/10.1097/WAD.0b013e318197852f
  45. Chow TW, Fam D, Graff-Guerrero A, Verhoeff NP, Tang-Wai DF, Masellis M, Black SE, Wilson AA, Houle S, Pollock BG. Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open-label pilot study. International Journal of Geriatric Psychiatry. 2013;28(3):319-325.  https://doi.org/10.1002/gps.3832
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.